NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

	Mar '21	Jun '21	Sep '21	Dec '21	Mar '22	Jun '22	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24
net income	-2.12K -	-928 56.31%	-888 4.31%	-101 88.63%	-2.71K 2,588.12%	-3.48K 28.21%	-2.99K 13.99%	-3.15K 5.21%	-3.89K 23.46%	-5.22K 34.35%	784K 15,104.78%	-2.95K 100.38%	-5.40K 83.19%
depreciation and amortization
deferred income tax
stock based compensation		2.63K -	-2.63K 200%	3.82K 245.17%		2.81K -	-2.81K 200%	5.11K 281.80%		1.78K -		2.80K -
change in working capital
accounts receivables
inventory
accounts payables
other working capital
other non cash items	2.12K -	-1.70K 180.13%	3.52K 306.70%	-3.72K 205.66%	2.71K 173.04%	3.48K 28.21%	2.99K 13.99%	3.15K 5.21%	3.89K 23.46%	5.22K 34.35%	-784K 15,104.78%	152 100.02%	5.40K 3,455.26%
net cash provided by operating activities						2.81K -	-2.81K 200%	5.11K 281.80%		1.78K -
investments in property plant and equipment
acquisitions net
purchases of investments
sales maturities of investments
other investing activites
net cash used for investing activites
debt repayment
common stock issued
common stock repurchased
dividends paid
other financing activites
net cash used provided by financing activities
effect of forex changes on cash
net change in cash						2.81K -	62K 2,107.98%	-855K 1,479.03%	-2.18M 155.09%	5.73M 362.68%	-2.33M 140.69%
cash at beginning of period	699 -						4.37M -	4.43M 1.42%	3.58M 19.28%	1.40M 60.94%	7.13M 409.80%
cash at end of period	699 -					2.81K -	4.43M 157,805.98%	3.58M 19.28%	1.40M 60.94%	7.13M 409.80%	4.80M 32.71%
operating cash flow						2.81K -	-2.81K 200%	5.11K 281.80%		1.78K -
capital expenditure
free cash flow						2.81K -	-2.81K 200%	5.11K 281.80%		1.78K -

NASDAQ:NRSN

NeuroSense Therapeutics Ltd.

Last Close

0.76

30/08 20:00

Market Cap

17.50M

Beta: -

Volume Today

1.35M

Avg: 65.36K

PE Ratio

−1.38

PFCF: -

Preview